Erasca reports early clinical responses for cancer drug ERAS-0015
Go back to Erasca reports early clinical responses for cancer drug ERAS-0015| (NASDAQ: ERAS) | Delayed: 13.50 +0.32 (2.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.18 | 52 Week High | $ | |||
| Open | $13.54 | 52 Week Low | $ | |||
| Day High | $13.99 | P/E | N/A | |||
| Day Low | $13.01 | EPS | $ | |||
| Volume | 5,394,333 | |||||
